deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT03774732

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG)

Sponsor: National Cancer Institute, France

Conditions Non Small Cell Lung Cancer Non Small Cell Lung Cancer Metastatic Non-Small Cell Carcinoma of Lung, TNM Stage 4
Interventions Chemotherapy Pembrolizumab Radiotherapy
Updated 15 times since 2019 Last updated: Feb 24, 2026 Started: Jan 24, 2018 Primary completion: Dec 22, 2026 Completion: Dec 22, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Non Small Cell Lung Cancer and Non Small Cell Lung Cancer Metastatic and is currently ongoing. National Cancer Institute, France leads this study, which shows 15 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~May 2020 · 11 months · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Jan 2024 · 16 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Sep 2025 · 11 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

15 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  2. Dec 2025 — Feb 2026 [monthly]

    Recruiting PHASE3

    Status: Active Not Recruiting → Recruiting

  3. Sep 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Oct 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  5. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE3

▶ Show 10 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  2. Jan 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

  3. Sep 2022 — Jan 2024 [monthly]

    Recruiting PHASE3

  4. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE3

  5. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  6. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

    Status: Suspended → Recruiting

  7. May 2020 — Aug 2020 [monthly]

    Suspended PHASE3

    Status: Recruiting → Suspended

  8. Jun 2019 — May 2020 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  9. Apr 2019 — Jun 2019 [monthly]

    Not Yet Recruiting PHASE3

  10. Jan 2019 — Apr 2019 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Jan 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute, France
  • UNICANCER
Data source: UNICANCER

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angers, France , Arras, France , Avignon, France , Beuvry, France , Blois, France , Bordeaux, France , Brest, France , Caen, France , Calais, France , Cannes, France and 32 more locations